Free Trial
NASDAQ:RXST

RxSight (RXST) Stock Price, News & Analysis

RxSight logo
$25.22 -0.85 (-3.26%)
Closing price 04:00 PM Eastern
Extended Trading
$25.22 0.00 (0.00%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About RxSight Stock (NASDAQ:RXST)

Key Stats

Today's Range
$25.11
$26.20
50-Day Range
$24.76
$35.84
52-Week Range
$24.64
$66.54
Volume
291,254 shs
Average Volume
528,134 shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.63
Consensus Rating
Moderate Buy

Company Overview

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Remove Ads

RxSight Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

RXST MarketRank™: 

RxSight scored higher than 58% of companies evaluated by MarketBeat, and ranked 460th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    RxSight has only been the subject of 4 research reports in the past 90 days.

  • Read more about RxSight's stock forecast and price target.
  • Earnings Growth

    Earnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of RxSight is -30.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of RxSight is -30.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    RxSight has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about RxSight's valuation and earnings.
  • Percentage of Shares Shorted

    6.81% of the float of RxSight has been sold short.
  • Short Interest Ratio / Days to Cover

    RxSight has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RxSight has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    RxSight does not currently pay a dividend.

  • Dividend Growth

    RxSight does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.81% of the float of RxSight has been sold short.
  • Short Interest Ratio / Days to Cover

    RxSight has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RxSight has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    RxSight has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for RxSight this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    2 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RxSight insiders have sold 141.44% more of their company's stock than they have bought. Specifically, they have bought $44,993.00 in company stock and sold $108,632.00 in company stock.

  • Percentage Held by Insiders

    Only 9.36% of the stock of RxSight is held by insiders.

  • Percentage Held by Institutions

    78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about RxSight's insider trading history.
Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

RXST Stock News Headlines

Please don’t die on me
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
Morgan Stanley Sticks to Their Buy Rating for RxSight (RXST)
RxSight price target lowered to $44 from $58 at BTIG
Wells Fargo Reaffirms Their Hold Rating on RxSight (RXST)
Stifel Nicolaus Sticks to Their Hold Rating for RxSight (RXST)
See More Headlines

RXST Stock Analysis - Frequently Asked Questions

RxSight's stock was trading at $34.38 at the start of the year. Since then, RXST shares have decreased by 26.8% and is now trading at $25.1540.
View the best growth stocks for 2025 here
.

RxSight, Inc. (NASDAQ:RXST) posted its earnings results on Tuesday, February, 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.25. The company had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative net margin of 23.92% and a negative trailing twelve-month return on equity of 14.00%.

RxSight (RXST) raised $125 million in an initial public offering on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

RxSight's top institutional shareholders include RA Capital Management L.P. (9.29%), Vanguard Group Inc. (5.91%), Bank of America Corp DE (5.36%) and Artisan Partners Limited Partnership (3.85%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Julie Andrews, Robert Keith Warner, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley.
View institutional ownership trends
.

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON).

Company Calendar

Last Earnings
2/25/2025
Today
3/13/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:RXST
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.63
High Stock Price Target
$73.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+104.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-48,610,000.00
Pretax Margin
-23.91%

Debt

Sales & Book Value

Annual Sales
$139.93 million
Price / Cash Flow
N/A
Book Value
$4.47 per share
Price / Book
5.65

Miscellaneous

Free Float
36,532,000
Market Cap
$1.02 billion
Optionable
Optionable
Beta
1.22
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:RXST) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners